Invivyd announces Phase 3 DECLARATION upsizing; new measles antibody VMS063

Invivyd, Inc.

DECLARATION Phase 3 COVID-19 prophylaxis study upsized by ~500 subjects; top-line results now expected in Q3 2026, shifted from mid-2026.
Pooled, blinded COVID-19 events at 1,500 subjects (Day 45) already support statistical power for high end of anticipated VYD2311 efficacy.
FDA alignment on initial Pediatric Study Plan for VYD2311 (DRUMMER study) for children aged 0-11 years, contingent on DECLARATION success.
New measles mAb candidate VMS063 targets F protein, shows potent in vitro neutralization (picogram/mL IC50s) across B3, D8, Edmonston lineages; IND-enablement started.
VMS063 is half-life extended, planned for treatment and prophylaxis in measles; U.S. measles incidence in 2026 on track to exceed 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.